NUTRITIONAL ASSESSMENT IN ANEMIC HEMODIALYSIS-PATIENTS TREATED WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN

被引:1
|
作者
BARANY, P [1 ]
PETTERSON, E [1 ]
AHLBERG, M [1 ]
HULTMAN, E [1 ]
BERGSTROM, J [1 ]
机构
[1] HUDDINGE UNIV HOSP, DEPT CLIN CHEM, S-14186 HUDDINGE, SWEDEN
关键词
ANEMIA; ERYTHROPOIETIN; HEMODIALYSIS; NUTRITION; UREMIA;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Nutritional status was assessed in 25 anemic hemodialysis patients before and during erythropoietin treatment. Nutritional assessment included regular blood chemistry determinations, anthropometric measurements, analysis of protein content in skeletal muscle, and estimation of daily protein intake from protein catabolic rate determinations (using urea kinetic modelling) and dialysis efficiency for urea. These measurements were done immediately prior to erythropoietin treatment, after anemia correction and after one year of maintenance erythropoietin treatment. Both relative body weights and subcutaneous fat stores were low at the start, but increased significantly (p < 0.05) during the study. Sixteen of the 25 patients gained weight and eight patients lost weight. The patients with weight gain had at the start of the study low weight indices (body weight 89.9 +/- 7.6% of ideal body weight, body mass index 20.6 +/- 1.6), significantly (p < 0.005) lower than the patients with weight loss. Although protein malnutrition was not obvious from arm anthropometrics, alkali soluble protein/DNA ratio or from serum albumin determinations, ASP/DNA ratio, increased in three of five patients investigated after one year on erythropoietin treatment. Neither protein catabolic rate nor dialysis efficiency changed significantly during the study. We conclude that anemia correction with erythropoietin has a positive effect on malnutrition in hemodialysis patients. In patients with underweight, an adjustment of fat stores was initially observed, followed possibly by an improvement in muscle protein content.
引用
收藏
页码:270 / 279
页数:10
相关论文
共 50 条
  • [1] RECOMBINANT-HUMAN-ERYTHROPOIETIN IN ANEMIC PATIENTS ON HEMODIALYSIS
    BOMMER, J
    MULLERBUHL, E
    RITZ, E
    EIFERT, J
    [J]. LANCET, 1987, 1 (8529): : 392 - 392
  • [2] LYMPHOCYTE SUBSETS IN HEMODIALYSIS-PATIENTS TREATED WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN
    UEKI, Y
    NAGATA, M
    MIYAKE, S
    TOMINAGA, Y
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 1993, 13 (04) : 279 - 287
  • [3] EFFECT OF RECOMBINANT-HUMAN-ERYTHROPOIETIN ON PLATELET-FUNCTION IN ANEMIC HEMODIALYSIS-PATIENTS
    MARTIN, MJ
    CERVERO, A
    SANCHEZ, M
    MOLL, R
    SANCHIS, J
    VILLARO, J
    PEREZ, A
    [J]. KIDNEY INTERNATIONAL, 1990, 37 (06) : 1585 - 1585
  • [4] FIBRINOLYTIC CAPACITY IN HEMODIALYSIS-PATIENTS TREATED WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN
    AUNSHOLT, NA
    AHLBOM, G
    STEFFENSEN, G
    GLUD, T
    [J]. NEPHRON, 1992, 62 (03): : 284 - 288
  • [5] PLASMA ENDOTHELIN IN HEMODIALYSIS-PATIENTS TREATED WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN
    BRUNET, P
    LOREC, AM
    LEONETTI, F
    ROUBICEK, C
    JABER, K
    ROUX, F
    BERLAND, Y
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1994, 9 (06) : 650 - 654
  • [6] RESISTANCE TO RECOMBINANT-HUMAN-ERYTHROPOIETIN IN HEMODIALYSIS-PATIENTS
    DRUEKE, TB
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 1990, 10 : 34 - 39
  • [7] HEMODYNAMIC AND VOLUME CHANGES BY RECOMBINANT-HUMAN-ERYTHROPOIETIN (RHUEPO) IN THE TREATMENT OF ANEMIC HEMODIALYSIS-PATIENTS
    HORI, K
    ONOYAMA, K
    ISEKI, K
    FUJIMI, S
    FUJISHIMA, M
    [J]. CLINICAL NEPHROLOGY, 1990, 33 (06) : 293 - 298
  • [9] EFFECT OF RECOMBINANT-HUMAN-ERYTHROPOIETIN ON HOSPITALIZATION OF HEMODIALYSIS-PATIENTS
    CHURCHILL, DN
    MUIRHEAD, N
    GOLDSTEIN, M
    POSEN, G
    FAY, WF
    BEECROFT, ML
    GORMAN, J
    TYLOR, DW
    [J]. CLINICAL NEPHROLOGY, 1995, 43 (03) : 184 - 188
  • [10] THE PHARMACOKINETICS AND PHARMACODYNAMICS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN IN HEMODIALYSIS-PATIENTS
    BROCKMOLLER, J
    KOCHLING, J
    WEBER, W
    LOOBY, M
    ROOTS, I
    NEUMAYER, HH
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (06) : 499 - 508